Scaffold Searching of FDA and EMA-Approved Drugs Identifies Lead Candidates for Drug Repurposing in Alzheimer’s Disease
Clinical trials of novel therapeutics for Alzheimer’s Disease (AD) have consumed a significant amount of time and resources with largely negative results. Repurposing drugs already approved by the Food and Drug Administration (FDA), European Medicines Agency (EMA), or Worldwide for another indicatio...
| Autori principali: | , , , |
|---|---|
| Natura: | Articolo |
| Lingua: | English |
| Pubblicazione: |
Frontiers Media S.A.
2021-10-01
|
| Serie: | Frontiers in Chemistry |
| Soggetti: | |
| Accesso online: | https://www.frontiersin.org/articles/10.3389/fchem.2021.736509/full |